DK0639079T3 - Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases - Google Patents
Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseasesInfo
- Publication number
- DK0639079T3 DK0639079T3 DK93910992T DK93910992T DK0639079T3 DK 0639079 T3 DK0639079 T3 DK 0639079T3 DK 93910992 T DK93910992 T DK 93910992T DK 93910992 T DK93910992 T DK 93910992T DK 0639079 T3 DK0639079 T3 DK 0639079T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitor
- methods
- mediated diseases
- tnf
- interleukin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
The invention relates to methods for treating or preventing diseases that are IL-1 mediated diseases or TNF mediated diseases, including arthritis, septic shock, inflammatory bowel disease, ischemia injury, reperfusion injury, pulmonary fibrosis and adult respiratory distress syndrome. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and a TNF inhibitor. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the TNF inhibitor is human recombinant 30kDa TNF inhibitor. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and a TNF inhibitor useful in such methods.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87634492A | 1992-04-30 | 1992-04-30 | |
PCT/US1993/004141 WO1993021946A1 (en) | 1992-04-30 | 1993-04-28 | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0639079T3 true DK0639079T3 (en) | 2000-06-13 |
Family
ID=25367492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93910992T DK0639079T3 (en) | 1992-04-30 | 1993-04-28 | Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0639079B1 (en) |
JP (2) | JPH07509223A (en) |
AT (1) | ATE188610T1 (en) |
AU (1) | AU672606B2 (en) |
CA (1) | CA2118119C (en) |
DE (1) | DE69327582T2 (en) |
DK (1) | DK0639079T3 (en) |
ES (1) | ES2142341T3 (en) |
GR (1) | GR3033144T3 (en) |
PT (1) | PT639079E (en) |
WO (1) | WO1993021946A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US7005413B1 (en) | 1995-12-22 | 2006-02-28 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
ATE406176T1 (en) | 1996-12-06 | 2008-09-15 | Amgen Inc | IL-1 INHIBITOR IN COMBINATION THERAPY FOR THE TREATMENT OF IL-1-MEDIATED DISEASES |
DE69740107D1 (en) | 1996-12-23 | 2011-03-10 | Immunex Corp | RECEPTOR ACTIVATOR OF NF-KAPPA B, RECEPTOR IS A MEMBER OF THE TNF RECEPTOR SUPERFAMILY |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
PT911342E (en) | 1997-04-15 | 2006-08-31 | Sankyo Co | NEW PROTEIN AND PROCESS TO PRODUCE |
SK288559B6 (en) | 1997-04-16 | 2018-05-02 | Amgen, Inc. | Nucleic acid, polypeptide, expression vector and host cell; osteoprotegerin binding protein and process for its preparation, antibody and medicament for preventing or treating bone diseases |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
JP4454859B2 (en) | 1998-11-13 | 2010-04-21 | イミュネックス・コーポレーション | Human TSLP DNA and polypeptides |
IL145714A0 (en) * | 1999-04-02 | 2002-07-25 | Interleukin Genetics Inc | Prediction of risk of interstitial lung disease |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
AU6078500A (en) * | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
EP1282435A2 (en) * | 2000-05-12 | 2003-02-12 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
EP2087908B1 (en) | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antibodies to opgl |
US7288633B2 (en) | 2001-07-23 | 2007-10-30 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
WO2003086289A2 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
CA2497884C (en) | 2002-09-06 | 2013-10-22 | Brian Varnum | Therapeutic human anti-il-1r1 monoclonal antibody |
CA2577631A1 (en) * | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
US7795385B2 (en) * | 2004-12-17 | 2010-09-14 | Bexar Global, Inc. | Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder |
PE20070684A1 (en) | 2005-11-14 | 2007-08-06 | Amgen Inc | RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US9383348B2 (en) | 2008-06-21 | 2016-07-05 | John E. Repine | Compositions and methods for treating lung disorders |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
CN102574907B (en) * | 2009-10-19 | 2015-10-21 | 韩诺生物制药株式会社 | The human tumor necrosis factor receptor I polypeptide of modifying or its fragment and prepare their method |
WO2011088120A1 (en) | 2010-01-15 | 2011-07-21 | Amgen Inc. | Antibody formulation and therapeutic regimens |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US20170174772A1 (en) | 2014-03-31 | 2017-06-22 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0148009B1 (en) * | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | Interleukin-1 inhibitors |
IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
JPH0357034U (en) * | 1989-10-11 | 1991-05-31 | ||
DE69230789T3 (en) * | 1991-01-18 | 2007-10-31 | Amgen Inc., Thousand Oaks | METHODS OF TREATING ILLNESSES RELEASED BY THE TUMOR NEKROSE FACTOR |
-
1993
- 1993-04-28 JP JP5519572A patent/JPH07509223A/en active Pending
- 1993-04-28 DE DE69327582T patent/DE69327582T2/en not_active Expired - Lifetime
- 1993-04-28 WO PCT/US1993/004141 patent/WO1993021946A1/en active IP Right Grant
- 1993-04-28 ES ES93910992T patent/ES2142341T3/en not_active Expired - Lifetime
- 1993-04-28 DK DK93910992T patent/DK0639079T3/en active
- 1993-04-28 CA CA002118119A patent/CA2118119C/en not_active Expired - Lifetime
- 1993-04-28 PT PT93910992T patent/PT639079E/en unknown
- 1993-04-28 AT AT93910992T patent/ATE188610T1/en active
- 1993-04-28 AU AU42294/93A patent/AU672606B2/en not_active Expired
- 1993-04-28 EP EP93910992A patent/EP0639079B1/en not_active Expired - Lifetime
-
2000
- 2000-04-04 GR GR20000400837T patent/GR3033144T3/en unknown
-
2001
- 2001-11-29 JP JP2001365407A patent/JP2002220342A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH07509223A (en) | 1995-10-12 |
PT639079E (en) | 2000-04-28 |
CA2118119C (en) | 2001-07-31 |
DE69327582D1 (en) | 2000-02-17 |
DE69327582T2 (en) | 2000-08-03 |
WO1993021946A1 (en) | 1993-11-11 |
JP2002220342A (en) | 2002-08-09 |
EP0639079B1 (en) | 2000-01-12 |
AU4229493A (en) | 1993-11-29 |
ATE188610T1 (en) | 2000-01-15 |
AU672606B2 (en) | 1996-10-10 |
CA2118119A1 (en) | 1993-11-11 |
GR3033144T3 (en) | 2000-08-31 |
ES2142341T3 (en) | 2000-04-16 |
EP0639079A1 (en) | 1995-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0639079T3 (en) | Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases | |
DE69738948D1 (en) | IL-1 inhibitor in combination therapy for the treatment of IL-1 mediated diseases | |
DK0713701T3 (en) | 2-Bromelatonin for the treatment of sleep disorders | |
DK0567566T3 (en) | Methods for the treatment of tumor necrosis factor-mediated diseases | |
NO943901D0 (en) | Methods and Preparations for the Treatment of Diseases with Interferon While Reducing Side Effects | |
EA200100872A1 (en) | COMPOSITION VALDEKOKSIBA | |
DE69334317D1 (en) | Purified DNAse forms | |
DE59007288D1 (en) | Use of the active ingredient azelastine and glycerin ethers to combat psoriasis diseases. | |
DE69733089D1 (en) | Treatment of osteotarthritis by administration of poly-N-acetyl-D-glucosamine | |
ATE481135T1 (en) | COMBINATION THERAPY WITH OMEGA INTERFERON FOR THE TREATMENT OF HEPATITIS C VIRUS OR YELLOW FEVER VIRUS INFECTIONS | |
ATE82294T1 (en) | THERAPEUTIC NUCLEOSIDES. | |
NO931413D0 (en) | METHODS AND PREPARATIONS FOR TREATMENT OF CELL PROLIFERATION DISEASES | |
DK347289A (en) | THERAPEUTIC RELATIONS | |
RU2003100517A (en) | NEW INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
NO971453D0 (en) | Use of bradykinin antagonists in the manufacture of drugs for the treatment of chronic fibrogenetic and acute liver diseases | |
JP2752250B2 (en) | Basic therapeutic agent with analgesic and anti-inflammatory action | |
LV12308A (en) | Compositions containing isothiazole derivatives and bioactive products are released from the tissue | |
DE69118847D1 (en) | Use of heptastigmine to treat cerebral icus | |
RU93004467A (en) | SUBSTITUTED PURIN ARABINOSES, THEIR APPLICATION, PHARMACEUTICAL COMPOSITION | |
RU93008990A (en) | METHOD FOR TREATMENT AND PREVENTION OF ACUTE ENDOMETRITIS IN COWS | |
TH13285EX (en) | Compounds used to treat degenerative diseases | |
RU93035856A (en) | METHOD OF TREATMENT OF OBLITERATED ENDARTERIITIS |